

impedimed

November 14, 2016

ImpediMed Establishes European CHF Medical Advisory Board

Brisbane, Australia, Carlsbad, Calif. and Bloomington, Minn. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that it has entered agreements to establish a European Medical Advisory Board to advise the Company on the clinical utility for the use of bioimpedance spectroscopy (BIS) in fluid detection for chronic heart failure patients.

European Medical Advisory Board members include:

- Stefan Anker, M.D., Ph.D. – Professor of Innovative Clinical Trials at University Medicine Göttingen (UMG), Göttingen, Germany. Past President of the Heart Failure Association of the European Society of Cardiology (2012-14)
- Gerasimos Filippatos, M.D. – Professor and Head of the Heart Failure Unit at Athens University Hospital Attikon, Greece. Past President of the Heart Failure Association of the European Society of Cardiology (2014-16)
- Marco Metra, M.D. – Professor of Cardiology at University of Brescia, Italy. Editor in Chief of European Journal of Heart Failure
- Piotr Ponikowski, M.D., Ph.D. – Professor and Head of Department of Heart Disease, Medical University Wroclaw Poland. Past President of the Heart Failure Association of the European Society of Cardiology (2010-12)

"ImpediMed is committed to expanding our technology into large chronic disease populations with unmet fluid management needs. Heart failure is a key focus for us. In conjunction with our esteemed US CHF Medical Advisory Board, this additional partnership with these remarkable European leaders and experts in the heart failure space give us unique clinical insight and scientific expertise to guide, drive and support our future success," said Richard Carreon, Managing Director & CEO of ImpediMed.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contacts:

For personal use only

In Australia:

Kyahn Williamson, Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

In the US:

Patti Hixon, Jones-Dilworth, Inc.

T: +1 512.633.1263

E: patti@jones-dilworth.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn. ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

###

For personal use only